Therapeutic outcomes of pemphigus in a referral service in Northern Brazil: a retrospective study of 32 patients

Abstract Background Pemphigus are rare chronic autoimmune blistering disorders with challenging therapeutic management. Objective To investigate the therapeutic outcomes of pemphigus patients admitted to a dermatology referral service in northern Brazil. Materials and methods We conducted a retrospective analysis of 32 patients with histopathological diagnosis of pemphigus between 2010 and 2016. Clinical and epidemiological data were collected. Therapeutic outcome was evaluated according to the criteria proposed by the International Pemphigus Committee. Pemphigus Disease Area Index (PDAI) was used to quantify disease severity. Results Of the 32 patients, 68.75% had pemphigus vulgaris (PV) and 31.25% had pemphigus foliaceus (PF). Female-to-male ratio was 1:1. The average age was 49.5 years. All patients received oral prednisone as the first-line therapy. Adjuvant immunosuppressive drugs were gradually added in refractory and/or severe cases. After 24 months of treatment, disease control and complete remission rates were 37.5% and 25%, respectively. The mortality rate was 9.37%. PDAI score was significantly lower at 24 months of therapeutic follow-up (p < .0001). Conclusion Therapeutic management with corticosteroids and/or immunosuppressive drugs was able to induce disease control/complete remission in most of patients. PDAI was a useful tool for objective assessment of disease severity during therapeutic follow-up.

[1]  G. Hans Filho,et al.  Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology* , 2019, Anais brasileiros de dermatologia.

[2]  L. Bañez,et al.  Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis , 2018, PloS one.

[3]  H. Shimizu,et al.  Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts. , 2018, Journal of the American Academy of Dermatology.

[4]  R. Pollmann,et al.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches , 2018, Clinical Reviews in Allergy & Immunology.

[5]  L. Naldi,et al.  Rituximab as first‐line adjuvant therapy for pemphigus: Retrospective analysis of long‐term outcomes at a single center , 2017, Journal of the American Academy of Dermatology.

[6]  M. Mustapa,et al.  British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017 , 2017, The British journal of dermatology.

[7]  M. Gdalevich,et al.  The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis. , 2015, Journal of the American Academy of Dermatology.

[8]  D. Zillikens,et al.  Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  C. A. Pires,et al.  Evaluation of cases of pemphigus vulgaris and pemphigus foliaceus from a reference service in Pará state, Brazil* , 2014, Anais brasileiros de dermatologia.

[10]  E. Hodak,et al.  Diagnosis and classification of pemphigus and bullous pemphigoid. , 2014, Autoimmunity reviews.

[11]  H. Kim,et al.  Long-Term Prognosis of Pemphigus in Korea: Retrospective Analysis of 199 Patients , 2011, Dermatology.

[12]  D. Murrell,et al.  Interventions for pemphigus vulgaris and pemphigus foliaceus. , 2009, The Cochrane database of systematic reviews.

[13]  H. Shimizu,et al.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.

[14]  T. Hashimoto Treatment strategies for pemphigus vulgaris in Japan , 2008 .

[15]  C. Chams‐Davatchi,et al.  Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. , 2007, Journal of the American Academy of Dermatology.

[16]  J. Roujeau,et al.  A single cycle of rituximab for the treatment of severe pemphigus. , 2007, The New England journal of medicine.

[17]  S. Fedele,et al.  High-dose intravenous 'pulse' methylprednisone in the treatment of severe oropharyngeal pemphigus: a pilot study. , 2002, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[18]  N. Fernandes,et al.  Treatment of pemphigus vulgaris and pemphigus foliaceus: experience with 71 patients over a 20 year period. , 2001, Revista do Instituto de Medicina Tropical de Sao Paulo.

[19]  R. Wolf,et al.  Early treatment of pemphigus does not improve the prognosis A review of 53 patients , 1995 .

[20]  S. Tavakolpour,et al.  Sixteen‐year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review , 2018, International immunopharmacology.

[21]  M. Shahidi-Dadras,et al.  Pulse versus oral methylprednisolone therapy in pemphigus vulgaris. , 2007, Archives of Iranian medicine.